05 Nov 2025 | 5 Mins Read
Novo Nordisk reduces weight loss drug growth forecast
Flipitmoney
Novo Nordisk lowered its growth expectations for obesity and diabetes treatments due to increased competition and pricing pressures. Net profit was $3.1 billion in line with expectations. The company expects 8-11% sales growth and 4-7% operating profit growth, down from previous forecasts of 8-14% and 4-10%. Sales of weight loss drug Wegovy rose 18% to 20 billion Danish kroner.